India’s first dengue vaccine moves closer to reality as phase 3 trial enrolment nears completion
India is getting closer to its first indigenous vaccine as the Medical Research Council of India (ICMR) and Pensia Biotech are ready to complete the nomination for the final phase of human tests by October 2025. The purpose of this vaccine is to handle the growing threat of Dengue, affecting millions of people annually. The vaccine has shown promising results in the preliminary stages, and if successful, will provide significant relief to India's stressful health care system, especially during the monsoon season when there are spike in dengue cases. Clinical studies are done in many places to ensure different population coverage. Pansia Biotech, known for its vaccine portfolio, works closely with ICMR to fulfill regulatory standards and expects to submit approval immediately after the test is completed. When this vaccine is approved, this vaccine can reduce hospitalization and reduce confusion, so that India's fight against mosquito diseases. This initiative also matches India's goal of becoming confidence in important health services.
Read full Story »Disclaimer: This preview includes title, image, and description automatically sourced from the original website (www.cnbctv18.com) using publicly available metadata / OG tags. All rights, including copyright and content ownership, remain with the original publisher. If you are the content owner and wish to request removal, please contact us from your official email to no_reply@newspaperhunt.com.
